TABLE 2.
Psychotic symptoms and MNFT levels at baseline and at follow‐up
| T1 | T2 | T2‐T1 (95% CI) | z (p) a | |
|---|---|---|---|---|
| n = 25 | n = 25 | |||
| PANSS total score | 84.4 ± 12.9 | 66.7 ± 13.5 | −17.9 (−24.70, −11.06) | 3.8 (<0.001) |
| P subscore | 25.6 ± 5.2 | 16.9 ± 5.6 | −8.6 (−10.98, −6.30) | 4.2 (<0.001) |
| N subscore | 18.2 ± 5.3 | 16.6 ± 4.0 | −1.5 (−3.93, 0.97) | 1.0 (0.30) |
| G subscore | 40.6 ± 6.7 | 33.2 ± 5.7 | −7.8 (−11.57, −3.95) | 3.2 (0.001) |
| Metabolites | ||||
| MNFT | 273,146.7 ± 210,146.7 | 335,688.1 ± 230,701.9 | 62,541 (−75,235, 200,318) | 1.3 (0.21) |
| MNFT (responder) | 166,878.8 ± 866,74.2 | 355,875.6 ± 282,535.8 | 188,996 (−19,252, 397,246) | 1.9 (0.059) |
| MNFT (non‐responder) | 343,991.9 ± 239,650.6 | 322,229.8 ± 198,589.7 | −21,762 (−211,563, 168,038) | 0.06 (0.96) |
| Lg (MNFT levels) | ||||
| MNFT | 5.3 ± 0.3 | 5.4 ± 0.3 | 0.09 (−0.10, 0.28) | 1.2 (0.24) |
| MNFT (responder) | 5.2 ± 0.2 | 5.4 ± 0.3 | 0.26 (−0.20, 0.54) | 1.8 (0.07) |
| MNFT (non‐responder) | 5.4 ± 0.3 | 5.4 ± 0.3 | −0.02 (−0.28, 0.25) | 0.0 (1.00) |
Abbreviations: MNFT, methyl n‐formylanthranilate; T1, at baseline; T2, at 4‐week follow‐up; T2−T1, the value in T2 minus the value in T1.
a
Paired samples t‐test (non‐parametric alternative Mann–Whitney U‐Test).